Fulcrum Therapeutics Inc. (FULC)
Fulcrum Therapeutics Statistics
Share Statistics
Fulcrum Therapeutics has 53.98M shares outstanding. The number of shares has increased by -12.91% in one year.
| Shares Outstanding | 53.98M |
| Shares Change (YoY) | -12.91% |
| Shares Change (QoQ) | -13.56% |
| Owned by Institutions (%) | 87.76% |
| Shares Floating | 47.84M |
| Failed to Deliver (FTD) Shares | 449 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 4.97M, so 9.22% of the outstanding shares have been sold short.
| Short Interest | 4.97M |
| Short % of Shares Out | 9.22% |
| Short % of Float | 10.93% |
| Short Ratio (days to cover) | 7.67 |
Valuation Ratios
The PE ratio is -4.25 and the forward PE ratio is -3.75. Fulcrum Therapeutics's PEG ratio is 0.13.
| PE Ratio | -4.25 |
| Forward PE | -3.75 |
| PS Ratio | 147.54 |
| Forward PS | 74.9 |
| PB Ratio | 1.76 |
| P/FCF Ratio | -4.52 |
| PEG Ratio | 0.13 |
Enterprise Valuation
Fulcrum Therapeutics Inc. has an Enterprise Value (EV) of 399.1M.
| EV / Earnings | -4.1 |
| EV / Sales | 142.28 |
| EV / EBITDA | -3.68 |
| EV / EBIT | -3.61 |
| EV / FCF | -4.36 |
Financial Position
The company has a current ratio of 17.71, with a Debt / Equity ratio of 0.05.
| Current Ratio | 17.71 |
| Quick Ratio | 17.71 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.4 |
| Cash Flow / Debt | -8.41 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.41% and return on capital (ROIC) is -44.98%.
| Return on Equity (ROE) | -0.41% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -44.98% |
| Revenue Per Employee | $62,333.33 |
| Profits Per Employee | $-2,163,000 |
| Employee Count | 45 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -71.67% in the last 52 weeks. The beta is 2.19, so Fulcrum Therapeutics's price volatility has been higher than the market average.
| Beta | 2.19 |
| 52-Week Price Change | -71.67% |
| 50-Day Moving Average | 4.09 |
| 200-Day Moving Average | 5.54 |
| Relative Strength Index (RSI) | 34.92 |
| Average Volume (20 Days) | 714.06K |
Income Statement
In the last 12 months, Fulcrum Therapeutics had revenue of 2.81M and earned -97.33M in profits. Earnings per share was -1.59.
| Revenue | 2.81M |
| Gross Profit | 2.81M |
| Operating Income | -110.66M |
| Net Income | -97.33M |
| EBITDA | -108.49M |
| EBIT | -110.66M |
| Earnings Per Share (EPS) | -1.59 |
Balance Sheet
The company has 25.56M in cash and 10.82M in debt, giving a net cash position of 14.74M.
| Cash & Cash Equivalents | 25.56M |
| Total Debt | 10.82M |
| Net Cash | 14.74M |
| Retained Earnings | -509.67M |
| Total Assets | 260.72M |
| Working Capital | 238.88M |
Cash Flow
In the last 12 months, operating cash flow was -90.97M and capital expenditures -508K, giving a free cash flow of -91.47M.
| Operating Cash Flow | -90.97M |
| Capital Expenditures | -508K |
| Free Cash Flow | -91.47M |
| FCF Per Share | -1.49 |
Margins
Gross margin is 100%, with operating and profit margins of -3.95K% and -3.47K%.
| Gross Margin | 100% |
| Operating Margin | -3.95K% |
| Pretax Margin | -3.47K% |
| Profit Margin | -3.47K% |
| EBITDA Margin | -3.87K% |
| EBIT Margin | -3.95K% |
| FCF Margin | -3.26K% |
Dividends & Yields
FULC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -49.53% |
| FCF Yield | -52.79% |
Analyst Forecast
The average price target for FULC is $4, which is 24.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $4 |
| Price Target Difference | 24.6% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 4.73 |
| Piotroski F-Score | 5 |